EyePoint Stock Plummets 71% After Drug Trial Failure, Market Reaction Questioned

EyePoint Pharmaceuticals' stock experienced a dramatic 71% drop following a drug trial failure, with some analysts suggesting the market reaction might be an overreaction.

17 Aug, 15:14 — 17 Aug, 15:14

Post Share

Sources

Showing 1 of 1 sources

Barron'sHigh2h ago

EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction. - Barron's

EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction. Barron's

Read full article →

PERSPECTA

PERSPECTA

EyePoint Stock Plummets 71% After Drug Trial Failure, Market Reaction Questioned

Sources

EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction. - Barron's

Related Stories

Norway's King Harald V Hospitalized

Metro Manila Inundated by Heavy Monsoon Rains

West Nile Fever Cases and Fatalities Reported in Serbia and North Macedonia

Five Teenagers Die in Ireland Driving Wrong Way on Motorway for Social Media Trend

PERSPECTA